We use cookies

Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.

You can change your choice at any time.

MMedXYNews
HomeVideos
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story
MedXY AI/MedXY News/Rheumatology

Rheumatology

Ask MedXY AI
What is the latest evidence?Key clinical updatesGuideline changes

Latest news

Can an 11β‑HSD1 Inhibitor Improve Prednisolone’s Benefit–Risk Ratio in Polymyalgia Rheumatica? Early Human Trial Suggests Feasibility
Diabetes & Endocrinologyglucocorticoid toxicityPolymyalgia Rheumatica

Can an 11β‑HSD1 Inhibitor Improve Prednisolone’s Benefit–Risk Ratio in Polymyalgia Rheumatica? Early Human Trial Suggests Feasibility

By MedXY|Dec 5, 2025

A single‑blind sequential cohort trial found that clofutriben, a selective 11β‑HSD1 inhibitor, reduced biomarkers of glucocorticoid toxicity while partially attenuating prednisolone efficacy at low doses; efficacy was restored at higher pre

EULAR 2025 Classification Criteria for Haemochromatosis Arthropathy: What Clinicians and Researchers Need to Know
newsEULAR 2025

EULAR 2025 Classification Criteria for Haemochromatosis Arthropathy: What Clinicians and Researchers Need to Know

By MedXY|Dec 4, 2025

EULAR’s first-ever, evidence-based classification criteria for haemochromatosis arthropathy (HA) provide an 8-item, 11-point score (≥5 yields 93.3% specificity, 71.4% sensitivity) to standardize research cohorts of C282Y homozygous patients

EAPSDAS: The First EULAR Disease Activity Score for Antiphospholipid Syndrome — What Clinicians Need to Know
newsantiphospholipid syndromeEULAR

EAPSDAS: The First EULAR Disease Activity Score for Antiphospholipid Syndrome — What Clinicians Need to Know

By MedXY|Dec 4, 2025

EULAR’s new antiphospholipid syndrome disease activity score (EAPSDAS) provides the first standardized, validated tool to measure APS activity across thrombotic, microvascular and obstetric manifestations — a major advance for clinical care

Long-Term Impact of Treat-to-Target Urate-Lowering Therapy on Ultrasound-Detected Crystal Depositions and Clinical Outcomes: Insights from the 5-Year NOR-Gout Study
Clinical Updatesgoutremission

Long-Term Impact of Treat-to-Target Urate-Lowering Therapy on Ultrasound-Detected Crystal Depositions and Clinical Outcomes: Insights from the 5-Year NOR-Gout Study

By MedXY|Dec 4, 2025

The 5-year NOR-Gout study demonstrates that sustained low serum urate via treat-to-target therapy leads to dissolution of crystal deposits, reduced flares, and increased remission rates, highlighting the clinical value of long-term urate co

Rapid, Durable Benefit of Upadacitinib Across Oligo‑ and Polyarticular Psoriatic Arthritis: Primary Findings from the Real‑World UPJOINT Study
newspsoriatic arthritisUpadacitinib

Rapid, Durable Benefit of Upadacitinib Across Oligo‑ and Polyarticular Psoriatic Arthritis: Primary Findings from the Real‑World UPJOINT Study

By MedXY|Dec 4, 2025

In the multicenter UPJOINT observational study, upadacitinib produced rapid and sustained improvements in minimal disease activity in both oligo- and polyarticular psoriatic arthritis over 48 weeks, with a safety profile consistent with pri

UPsA Ultrasound Scores Bring Quantitative Activity and Damage Assessment to Psoriatic Arthritis — Feasible, Responsive Tools from a Multicentre Italian Study
newsdisease activitypsoriatic arthritis

UPsA Ultrasound Scores Bring Quantitative Activity and Damage Assessment to Psoriatic Arthritis — Feasible, Responsive Tools from a Multicentre Italian Study

By MedXY|Dec 4, 2025

The UPsA activity and damage ultrasound scores (and a simplified sUPsA) were developed and internally validated in 312 PsA patients; they correlate moderately with clinical measures, are responsive to change (SRM overall 0.63; 1.03 in MDA a

Sustained Treat‑to‑Target Urate‑Lowering Therapy Clears Crystal Deposits and Cuts Flares: 5‑Year NOR‑Gout Follow‑Up
newsgoutultrasound

Sustained Treat‑to‑Target Urate‑Lowering Therapy Clears Crystal Deposits and Cuts Flares: 5‑Year NOR‑Gout Follow‑Up

By MedXY|Dec 3, 2025

Five‑year follow‑up of the NOR‑Gout treat‑to‑target urate‑lowering therapy program shows durable serum urate control, marked reduction and frequent dissolution of ultrasound‑detected MSU deposits, and a low residual flare rate linked to hig

Ten-Year TOPKAT Follow-up: Partial (Unicompartmental) Knee Replacement Matches Total Replacement Clinically and Is More Cost-Effective
newsCost-Effectivenesstotal knee replacement

Ten-Year TOPKAT Follow-up: Partial (Unicompartmental) Knee Replacement Matches Total Replacement Clinically and Is More Cost-Effective

By MedXY|Dec 1, 2025

The 10-year TOPKAT randomized trial found no clinically important difference in Oxford Knee Score between partial (PKR) and total knee replacement (TKR) for medial compartment osteoarthritis, similar revision/reoperation rates, and cost-eff

Early IL‑17A Blockade vs Step‑Up Therapy in Psoriatic Arthritis: STAMP trial shows no superior 6‑month benefit for secukinumab-first treat‑to‑target strategy
newspsoriatic arthritissecukinumab

Early IL‑17A Blockade vs Step‑Up Therapy in Psoriatic Arthritis: STAMP trial shows no superior 6‑month benefit for secukinumab-first treat‑to‑target strategy

By MedXY|Dec 1, 2025

The STAMP randomized trial found that a treat‑to‑target strategy starting with secukinumab plus methotrexate did not achieve superior 6‑month ACR50 rates versus a conventional methotrexate‑first step‑up approach; 12‑month outcomes were simi

Predicting Rare but Serious Harm: A Validated 100‑Day Risk Model for Allopurinol‑Induced Severe Cutaneous Adverse Reactions
DermatologyCKDPrognostic Model

Predicting Rare but Serious Harm: A Validated 100‑Day Risk Model for Allopurinol‑Induced Severe Cutaneous Adverse Reactions

By MedXY|Dec 1, 2025

A large UK cohort study developed and externally validated a 100‑day prognostic model for allopurinol‑induced severe cutaneous adverse reactions (SCAR). Key predictors include age, CKD stage, high initial dose, and Asian ethnicity; discrimi

Deep learning classifies focus score and Sjögren’s disease from minor salivary gland biopsies and highlights a CD8+ acinar pattern
AImachine learningpathology

Deep learning classifies focus score and Sjögren’s disease from minor salivary gland biopsies and highlights a CD8+ acinar pattern

By MedXY|Dec 1, 2025

A multicentre deep‑learning model reliably classified biopsy focus score and ACR‑EULAR–defined Sjögren’s disease (AUROC ≈0.88–0.89) and identified a novel CD8+ T‑cell peri‑acinar pattern associated with disease; prospective validation is ne

High Cardiovascular Risk but Poor Risk-factor Control in Antiphospholipid Syndrome — Worse in Primary APS than SLE-related APS
Cardiologyantiphospholipid syndromecardiovascular risk

High Cardiovascular Risk but Poor Risk-factor Control in Antiphospholipid Syndrome — Worse in Primary APS than SLE-related APS

By MedXY|Nov 30, 2025

A multinational cross-sectional study of 1003 people with antiphospholipid syndrome (APS) found high prevalence of hypertension, hyperlipidaemia, obesity and smoking, with suboptimal attainment of guideline targets — particularly among thos

FcRn blockade with nipocalimab reduces disease activity in moderate‑to‑severe Sjögren’s syndrome: positive phase 2 DAHLIAS results
newsautoantibodiesnipocalimab

FcRn blockade with nipocalimab reduces disease activity in moderate‑to‑severe Sjögren’s syndrome: positive phase 2 DAHLIAS results

By MedXY|Nov 27, 2025

In DAHLIAS, intravenous nipocalimab 15 mg/kg every 2 weeks for 22 weeks significantly reduced ClinESSDAI scores versus placebo in anti‑Ro seropositive patients with moderate‑to‑severe Sjögren’s disease, with a safety profile similar to plac

Whole‑Genome Sequencing Reveals HLA, FCGR2B and Complement C4 Copy‑Number as Distinct Genetic Drivers of IgG4‑Related Disease in Japan
newsHLAwhole-genome sequencing

Whole‑Genome Sequencing Reveals HLA, FCGR2B and Complement C4 Copy‑Number as Distinct Genetic Drivers of IgG4‑Related Disease in Japan

By MedXY|Nov 25, 2025

A Japanese whole‑genome sequencing study identifies FCGR2B, specific HLA amino‑acid residues, and complement C4 copy‑number variation as independent genetic risk factors for IgG4‑related disease, with PTCH1 and a lncRNA linked to Mikulicz’s

Dual IL‑17A/IL‑17F blockade with sonelokimab produces robust clinical responses in active psoriatic arthritis: phase 2 randomized trial
Dermatologybiologicspsoriatic arthritis

Dual IL‑17A/IL‑17F blockade with sonelokimab produces robust clinical responses in active psoriatic arthritis: phase 2 randomized trial

By MedXY|Nov 12, 2025

A phase 2 randomized, placebo‑controlled trial found sonelokimab — a nanobody that inhibits IL‑17A and IL‑17F — produced significant improvements in joint and skin outcomes in active psoriatic arthritis versus placebo, with an acceptable sh

Dual CD19/BCMA CAR‑T Cells Produce Deep, Durable Remissions in Refractory SLE — Phase 1 Data Show Promise for a Curative Approach
Hematology-OncologyBCMACAR‑T

Dual CD19/BCMA CAR‑T Cells Produce Deep, Durable Remissions in Refractory SLE — Phase 1 Data Show Promise for a Curative Approach

By MedXY|Nov 12, 2025

In a phase 1 trial, co‑infused autologous CD19- and BCMA-targeting CAR‑T cells produced 80% LLDAS/DORIS remission at 12 weeks in 15 refractory SLE patients, with manageable toxicity and evidence of eradication of autoreactive B‑cell and pla

newsknee osteoarthritispatient-reported outcomes

Intra-articular Hyaluronic Acid Injections: Long-Term Benefits in Early-Stage Knee Osteoarthritis and Older Women

By MedXY|Nov 4, 2025

Systematic review of 71 RCTs reveals that intra-articular hyaluronic acid injections offer initial symptom worsening but significant long-term relief, especially in early-stage knee osteoarthritis and older women; molecular weight’s role re

GZMK+ CD8+ T Cells Drive Selective Acinar Cell Loss and Interferon Signaling in Sjögren’s Disease
newsCD8 T cellssingle-cell transcriptomics

GZMK+ CD8+ T Cells Drive Selective Acinar Cell Loss and Interferon Signaling in Sjögren’s Disease

By MedXY|Nov 4, 2025

Single-cell and spatial multi-omics reveal loss of a PRR4⁺CST3⁺ seromucous acinar population and accumulation of GZMK⁺CD8⁺ T cells that induce IFN-driven epithelial dysfunction in Sjögren’s disease.

Outcomes of Maintenance Immunotherapy in Susac Syndrome
NeurologyAutoimmune encephalopathycase report

Outcomes of Maintenance Immunotherapy in Susac Syndrome

By MedXY|Nov 2, 2025

This case series evaluates relapse rates associated with various maintenance immunotherapies in 54 patients with Susac syndrome, highlighting treatment efficacy and challenges in managing this rare autoimmune disorder.

Partitioning Knee Osteoarthritis Genetic Risk by BMI Association Clarifies Prediction and Mechanisms
newsBMIgenetics

Partitioning Knee Osteoarthritis Genetic Risk by BMI Association Clarifies Prediction and Mechanisms

By MedXY|Nov 2, 2025

Partitioning a knee osteoarthritis polygenic score into BMI-associated and BMI-independent components clarifies genetic contributions, improves interpretability, and offers a path to tailored prediction and prevention.

Prev
4 / 7
1234567
Next
Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
Cardiology
Precision Medicine for Long QT Syndrome Type 2: Lumacaftor Corrects Trafficking Defects and Shortens QT Interval
General Surgery
Optimizing Postoperative Opioid Prescriptions After Intra-Abdominal Cancer Surgery: Comparing the 5x-Multiplier and 3-Tier Models

Browse by specialty

Open language-specific specialty feeds and department pages.

news7335 articlesCardiology1451 articlesClinical Updates1378 articlesOncology1254 articlesDiabetes & Endocrinology929 articlesNeurology889 articlesPublic Health637 articlesGastroenterology622 articles
Hematology-Oncology
562 articles
Pediatrics537 articles
Internal Medicine486 articles